Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Elixinol Global.
RELATED STOCKHEAD STORIES
Health & Biotech
Weed week: America says no to munchies
IPO Watch
IPOs of 2018: The few that floated when most didn’t
Health & Biotech
US Congress has two weeks left to vote on legalising hemp farming
Health & Biotech
Weed week: wtf happened with MMJ?
Health & Biotech
Weed week: here’s all the news driving the cannabis market (including hemp gin)
Health & Biotech
Elixinol’s big shareholders now own less of the cannabis stock after $40m fund raising
IPO Watch
IPO Watch: CannVaLate plans $65m ASX debut ahead of a rash of cannabis floats
Health & Biotech
These seven ASX-listed pot stocks are hoping for a US high
Health & Biotech
Rhinomed does US deal to put cannabis up your nose
Health & Biotech
Elixinol goes big in Japan, takes control of local biz
Health & Biotech
Why this ASX cannabis stock is actually turning a profit
Health & Biotech
Elixinol says it’s the first ASX cannabis stock to turn a profit
Health & Biotech
The US is already a monster cannabis market – and it’s not even legal there yet
IPO Watch
Miss out on another IPO? Here’s why retail investors get dudded in ASX floats
Health & Biotech
US Senate passes hemp law, opens door to legal cannabis market
Health & Biotech
Here’s how much money ASX cannabis stocks made last quarter
Health & Biotech